MannKind COO Hakan Edstrom appointed CEO after founder steps down

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.

MannKind COO Hakan Edstrom appointed CEO after founder steps down

MannKind ($MNKD) announced that Hakan Edstrom has been promoted to company CEO. On Monday, former CEO and founder Alfred Mann announced his retirement and will begin transitioning to his new role as executive chairman. Edstrom has served as president and COO of MannKind since 2001. In a statement, Edstrom said he is honored to succeed Mann and that he is "truly excited to lead MannKind at this critical juncture." Prior to his work at MannKind, Edstrom was employed at Bausch & Lomb and Pharmacia. Throughout his career spanning nearly 6 decades, Mann founded and largely funded 14 companies, 9 of which were acquired at a total of nearly $8 billion. Three became publicly traded, including MannKind. Release

MannKind
Hakan Edstrom was named CEO.


Keryx COO Greg Madison begins transition to CEO

Greg Madison, who joined the company in February 2014 as COO, was named the incoming CEO of Keryx Biopharmaceuticals ($KERX) on Monday. Madison will replace Ron Bentsur--who has served as the company's CEO for the past 5 years--after Bentsur's contract ends in May. Before joining Keryx, Madison served as executive vice president and COO of AMAG Pharmaceuticals and spent 12 years at Genzyme/Sanofi ($SNY), including a stint as general manager of that company's renal division. "With an exceptional team in place, a truly differentiated product, and a deep-rooted commitment to the renal community, I am confident that we will build a leading renal franchise, delivering value to all stakeholders--patients, physicians, providers, employees and our shareholders," Madison said in a statement. Release

Keryx
Greg Madison was named the incoming CEO.


KaloBios CEO David Pritchard retires following PhII trial failure

David Pritchard, president and CEO of KaloBios ($KBIO), announced his retirement effective immediately and has resigned his position on the company's board, following a clinical trial failure. Herb Cross, CFO, will serve as interim CEO pending a search for a new executive. Pritchard's retirement comes days after KaloBios announced that its Phase II KB001-A study for lung infections in cystic fibrosis patients failed to meet its primary endpoint; development of KB001-A was halted. The news decimated KaloBios' shares, sending them down more than 60% to less than 50 cents per share. Ted Love, the company's board chair, said Pritchard's retirement comes at an opportune time as the company shifts its focus to oncology. Release

KaloBios
David Pritchard, president and CEO, has retired.


Biotech

> Batu Biologics has appointed Dr. Alan Lewis as chairman of the board of directors. Release

> Seres Health has appointed Dr. Michele "Shelley" Trucksis as executive vice president and chief medical officer. Release

> Dr. Alan Burnett joins CTI BioPharma ($CTIC) as strategic leader for myeloid diseases from Cardiff University. Release

> ContraVir Pharmaceuticals names Dr. John Sullivan-Bolyai as chief medical officer. Release

> ProteoTech appointed Roger Flugel as its new CEO. Release

> Filipe Gaspar joined Hovione as the company's vice president of R&D. Release

> AmnioLife appointed Andrew Hoover as its chief financial officer. Release

> Arvinas brought on Manuel Litchman as its president and CEO. Release

> Apricus Biosciences hired Catherine Bovenizer as its vice president of finance and chief accounting officer. Release

> Oryzon Genomics appointed Greg Weaver as its global chief financial officer. Release

> Eliot Forster joined Immunocore as the company's CEO. Release

> Cytovance Biologics brought on Seth Fisher as its director of purification development in its R&D division. Release

> BioPharma Services appointed Dr. Janice Faulknor as its new medical director. Release

> OMNIlife science hired Steven Nunes as its vice president of market development. Release

> CiToxLAB brought on Philippe Ancian as its senior director of biomarkers. Release

> Dr. Steven Fruchtman joined Onconova Therapeutics ($ONTX) as its chief medical officer. Release

Pharma

> Astellas Pharma has named Eric Terhaerdt senior vice president of global development operations. Release

Medical Devices

> Sharon Schulzki, former Depuy Synthes Spine VP of surgical affairs, joined Tissue Regeneration Systems as senior vice president of business development. Release

CRO

> SynteractHCR has appointed Dr. James Cappola as medical director, Gary Urban as director of quality assurance and Barbara Falk as safety surveillance manager, EMEA. Release

 

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.